Amway’s global momentum in healthspan innovation helped drive $7.3 billion in 2025 sales, while Taiwan strengthened its role as a regional powerhouse with seven consecutive years of growth. Through product innovation, entrepreneurial opportunity, and long-term community engagement, Amway Taiwan continues to build on its 40-plus years of local impact.
Roche underscores its long-term commitment to Taiwan’s Healthy Taiwan vision through sustained R&D investment, clinical trials, and real-world data supporting precision medicine. By advancing patient access and advocating for value-based healthcare, Roche aims to help Taiwan build a more innovation-friendly and sustainable biomedical ecosystem.
Pfizer Taiwan’s latest national honors highlight its continued role in advancing vaccine innovation, oncology treatment, and Taiwan’s broader public health resilience.
Herbalife Taiwan is building trust through transparent regulatory engagement, distributor education, and compliance systems spanning product quality, ethics, and consumer protection.
Johnson & Johnson Taiwan is advancing patient access, precision diagnosis, and coordinated care to support the Healthy Taiwan vision and help more patients benefit from innovation earlier.
Coupang is expanding its long-term investments in Taiwan, using AI-driven logistics and digital retail capabilities to improve speed, service, and customer experience. As one of Coupang’s key growth markets, Taiwan is also positioned to support deeper U.S.-Taiwan economic ties and broader digital innovation across Asia.
Moderna Taiwan is advancing mRNA science, partnerships, and local talent development to support healthcare innovation and long-term health preparedness in Taiwan.
Taiwan has made major progress in hepatitis prevention, but chronic hepatitis B continues to drive a significant share of liver cancer cases. As new therapies, earlier intervention, and more targeted screening reshape care, stronger policy support could help Taiwan move toward the next phase of liver disease control.
Bayer Taiwan’s innovation pipeline reflects a broader shift in chronic care, with earlier intervention, longer-lasting treatments, and improved access helping patients manage disease more sustainably over time.
Taiwan has built a strong reputation for broad access to innovative medicines, but the next wave of precision therapies and diagnostics will require more adaptive assessment, reimbursement, and funding pathways.
